DrugPatentWatch Database Preview
Investigational Drug Information for Guadecitabine
Email this page to a colleague
What is the drug development status for Guadecitabine?
Guadecitabine is an investigational drug.
There have been 27 clinical trials for Guadecitabine.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 19th 2015.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Carcinoma. The leading clinical trial sponsors are Astex Pharmaceuticals, Astex Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are twenty US patents protecting this investigational drug and one hundred and sixty-two international patents.
Summary for Guadecitabine
| US Patents | 20 |
| International Patents | 162 |
| US Patent Applications | 67 |
| WIPO Patent Applications | 49 |
| Japanese Patent Applications | 30 |
| Clinical Trial Progress | Phase 3 (2015-03-19) |
| Vendors | 13 |
Recent Clinical Trials for Guadecitabine
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | National Cancer Institute (NCI) | Phase 2 |
| A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | Astex Pharmaceuticals, Inc. | Phase 2 |
| A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | Bristol-Myers Squibb | Phase 2 |
Clinical Trial Summary for Guadecitabine
Top disease conditions for Guadecitabine
Top clinical trial sponsors for Guadecitabine
US Patents for Guadecitabine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Guadecitabine | ⤷ Try it Free | Using DNA methyltransferase inhibitors to treat calcific aorta valve disease | Mayo Foundation for Medical Education and Research (Rochester, MN) | ⤷ Try it Free |
| Guadecitabine | ⤷ Try it Free | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (Cambridge, MA) | ⤷ Try it Free |
| Guadecitabine | ⤷ Try it Free | Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in ovarian cancer | UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD) | ⤷ Try it Free |
| Guadecitabine | ⤷ Try it Free | Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in lung cancer | UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD) | ⤷ Try it Free |
| Guadecitabine | ⤷ Try it Free | SYK inhibitors | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Guadecitabine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Guadecitabine | Australia | AU2014354775 | 2033-11-27 | ⤷ Try it Free |
| Guadecitabine | Brazil | BR112016011949 | 2033-11-27 | ⤷ Try it Free |
| Guadecitabine | Canada | CA2931458 | 2033-11-27 | ⤷ Try it Free |
| Guadecitabine | China | CN105934438 | 2033-11-27 | ⤷ Try it Free |
| Guadecitabine | European Patent Office | EP3074411 | 2033-11-27 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
